Literature DB >> 21436714

Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South Africa.

Stephen D Lawn1, Lucy Campbell, Richard Kaplan, Andrew Boulle, Morna Cornell, Bernhard Kerschberger, Carl Morrow, Francesca Little, Matthias Egger, Robin Wood.   

Abstract

We studied the time interval between starting tuberculosis treatment and commencing antiretroviral treatment (ART) in HIV-infected patients (n = 1433; median CD4 count 71 cells per microliter, interquartile range: 32-132) attending 3 South African township ART services between 2002 and 2008. The overall median delay was 2.66 months (interquartile range: 1.58-4.17). In adjusted analyses, delays varied between treatment sites but were shorter for patients with lower CD4 counts and those treated in more recent calendar years. During the most recent period (2007-2008), 4.7%, 19.7%, and 51.1% of patients started ART within 2, 4, and 8 weeks of tuberculosis treatment, respectively. Operational barriers must be tackled to permit further acceleration of ART initiation as recommended by 2010 WHO ART guidelines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21436714      PMCID: PMC3717455          DOI: 10.1097/QAI.0b013e3182199ee9

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  18 in total

1.  Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa.

Authors:  Ingrid V Bassett; Bingxia Wang; Senica Chetty; Janet Giddy; Elena Losina; Matilda Mazibuko; Benjamin Bearnot; Jenny Allen; Rochelle P Walensky; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2010-10-01       Impact factor: 9.079

2.  Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design.

Authors:  Stephen D Lawn; Landon Myer; Catherine Orrell; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2005-12-02       Impact factor: 4.177

3.  Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.

Authors:  Matthew P Fox; Ian M Sanne; Francesca Conradie; Jennifer Zeinecker; Catherine Orrell; Prudence Ive; Mohammed Rassool; Marjorie Dehlinger; Charles van der Horst; James McIntyre; Robin Wood
Journal:  AIDS       Date:  2010-08-24       Impact factor: 4.177

4.  Timing of initiation of antiretroviral drugs during tuberculosis therapy.

Authors:  Salim S Abdool Karim; Kogieleum Naidoo; Anneke Grobler; Nesri Padayatchi; Cheryl Baxter; Andrew Gray; Tanuja Gengiah; Gonasagrie Nair; Sheila Bamber; Aarthi Singh; Munira Khan; Jacqueline Pienaar; Wafaa El-Sadr; Gerald Friedland; Quarraisha Abdool Karim
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 5.  Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections.

Authors:  Stephen D Lawn; M Estée Török; Robin Wood
Journal:  Curr Opin Infect Dis       Date:  2011-02       Impact factor: 4.915

6.  Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa.

Authors:  Mweete D Nglazi; Stephen D Lawn; Richard Kaplan; Katharina Kranzer; Catherine Orrell; Robin Wood; Linda-Gail Bekker
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

7.  Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial.

Authors:  Ian Sanne; Catherine Orrell; Matthew P Fox; Francesca Conradie; Prudence Ive; Jennifer Zeinecker; Morna Cornell; Christie Heiberg; Charlotte Ingram; Ravindre Panchia; Mohammed Rassool; René Gonin; Wendy Stevens; Handré Truter; Marjorie Dehlinger; Charles van der Horst; James McIntyre; Robin Wood
Journal:  Lancet       Date:  2010-07-03       Impact factor: 79.321

8.  Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa.

Authors:  Andrew Boulle; Gilles Van Cutsem; Katherine Hilderbrand; Carol Cragg; Musaed Abrahams; Shaheed Mathee; Nathan Ford; Louise Knight; Meg Osler; Jonny Myers; Eric Goemaere; David Coetzee; Gary Maartens
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

9.  Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa.

Authors:  David Coetzee; Katherine Hildebrand; Andrew Boulle; Gary Maartens; Francoise Louis; Veliswa Labatala; Hermann Reuter; Nonthutuzelo Ntwana; Eric Goemaere
Journal:  AIDS       Date:  2004-04-09       Impact factor: 4.177

10.  Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease.

Authors:  Stephen D Lawn; David J Edwards; Katharina Kranzer; Monica Vogt; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

View more
  22 in total

1.  Outcomes in HIV-infected adults with tuberculosis at clinics with and without co-located HIV clinics in Botswana.

Authors:  A B Schwartz; N Tamuhla; A P Steenhoff; K Nkakana; R Letlhogile; T R Chadborn; M Kestler; N M Zetola; S Ravimohan; G P Bisson
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

2.  Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.

Authors:  Rosalind Parkes-Ratanshi; Katie Wakeham; Jonathan Levin; Deodata Namusoke; James Whitworth; Alex Coutinho; Nathan Kenya Mugisha; Heiner Grosskurth; Anatoli Kamali; David G Lalloo
Journal:  Lancet Infect Dis       Date:  2011-10-06       Impact factor: 25.071

3.  The Impact of Implementation Fidelity on Mortality Under a CD4-Stratified Timing Strategy for Antiretroviral Therapy in Patients With Tuberculosis.

Authors:  Monita R Patel; Daniel Westreich; Marcel Yotebieng; Mbonze Nana; Joseph J Eron; Frieda Behets; Annelies Van Rie
Journal:  Am J Epidemiol       Date:  2015-03-18       Impact factor: 4.897

4.  Delayed antiretroviral therapy despite integrated treatment for tuberculosis and HIV infection.

Authors:  M R Patel; M Nana; M Yotebieng; M Tabala; F Behets; A Van Rie
Journal:  Int J Tuberc Lung Dis       Date:  2014-06       Impact factor: 2.373

Review 5.  Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa.

Authors:  Stephen D Lawn; Anthony D Harries; Graeme Meintjes; Haileyesus Getahun; Diane V Havlir; Robin Wood
Journal:  AIDS       Date:  2012-11-13       Impact factor: 4.177

6.  Antiretroviral treatment uptake in patients with HIV-associated TB attending co-located TB and ART services.

Authors:  Mweete Debra Nglazi; Richard Kaplan; Judy Caldwell; Neshaan Peton; Stephen D Lawn; Robin Wood; Linda-Gail Bekker
Journal:  S Afr Med J       Date:  2012-10-22

7.  Timing of antiretroviral therapy in Cambodian hospital after diagnosis of tuberculosis: impact of revised WHO guidelines.

Authors:  Kimcheng Choun; Reaksmey Pe; Sopheak Thai; Natalie Lorent; Lutgarde Lynen; Johan van Griensven
Journal:  Bull World Health Organ       Date:  2012-12-12       Impact factor: 9.408

8.  Integrating tuberculosis and HIV services in rural Kenya: uptake and outcomes.

Authors:  P Owiti; R Zachariah; K Bissell; A M V Kumar; L Diero; E J Carter; A Gardner
Journal:  Public Health Action       Date:  2015-03-21

9.  Changes in the timing of antiretroviral therapy initiation in HIV-infected patients with tuberculosis in Uganda: a study of the diffusion of evidence into practice in the global response to HIV/AIDS.

Authors:  Tara Vijayan; Fred C Semitala; Nicholas Matsiko; Patrick Elyanu; Jennifer Namusobya; Diane V Havlir; Moses Kamya; Elvin H Geng
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

Review 10.  Integrating Human Immunodeficiency Virus and Reproductive, Maternal and Child, and Tuberculosis Health Services Within National Health Systems.

Authors:  Dvora Joseph Davey; Landon Myer; Elizabeth Bukusi; Doreen Ramogola-Masire; William Kilembe; Jeffrey D Klausner
Journal:  Curr HIV/AIDS Rep       Date:  2016-06       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.